Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.

The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predictors of these CoRs could provide insight into vacc...

Full description

Bibliographic Details
Main Authors: Erica Andersen-Nissen, Andrew Fiore-Gartland, Lamar Ballweber Fleming, Lindsay N Carpp, Anneta F Naidoo, Michael S Harper, Valentin Voillet, Nicole Grunenberg, Fatima Laher, Craig Innes, Linda-Gail Bekker, James G Kublin, Ying Huang, Guido Ferrari, Georgia D Tomaras, Glenda Gray, Peter B Gilbert, M Juliana McElrath
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-03-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1009363

Internet

https://doi.org/10.1371/journal.ppat.1009363

Similar Items